Abstract: Triple-negative breast cancer （TNBC）is a subtype of breast cancer, and it is characterized by an aggressive clinical course with a poor prognosis. Treatment for TNBC has attracted much attention in recent years, however, there is no standard treatment for TNBC in clinical setting. The pCR rates of neoadjuvant chemotherapy in TNBC ranges from 12% to 48% in the current published data, and it is higher than that in other types of breast cancer, however, the fluctuating range of the TNBC’s pCR is large in literature. Although the administration of adjuvant chemotherapy for early TNBC is controversial, the regimen without anthracyclines is reported to be suitable for early TNBC patients. Standard cytotoxic agents including taxanes and anthracyclines are still the main choices for TNBC salvage treatment, and the combination with gemcitabine or capecitabine may improve the overall survival. Poly (ADP-ribose) polymerase (PARP) is a new molecular target for TNBC in ongoing studies. Further research on the target-inhibitors such as BSI-201and Olaparib will provide more effective choices to clinical treatment.